An employee of the FCB-Pharmicell holds its stem cell medication Hearticellgram-AMI as she poses for a photograph at the company's main office in Seongnam, near Seoul, June 28, 2011. South Korea all but put stem cell research into the deep freeze after a pre-eminent scientist, Hwang Woo-suk, was found guilty of fraud for his work in the field in 2005. The state Korea Food and Drug Administration's (KFDA) approval for the sale of the Hearticellgram-AMI treatment, developed by FCB-Pharmicell, from July 1 signals an ambitious new push to put research in the field back on the frontline. Picture taken on June 28, 2011. To match Insight KOREA-STEMCELL/ REUTERS/Jo Yong-Hak (SOUTH KOREA - Tags: HEALTH BUSINESS SCI TECH)